Trial Search Results

Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Funded by Toyo Shinyaku Co Ltd

Stanford Investigator(s):

Intervention(s):

  • Drug: Pine Bark Extract (Flavangenol®)

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) <
   100 mmHg

   - Body mass index (BMI) 25.0-34.9

   - Triglycerides (TG) < 450 mg/dL

   - Low Density Lipoprotein (LDL) < 200 mg/dL

   - Fasting blood glucose (FBG) < 126 mg/dL

Exclusion Criteria:

   - DBP > 95 mmHg

   - LDL > 170 mg/dL

   - TG > 300 mg/dL

   - FBG > 110 mg/dL

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rebbeca Drieling
6507236528
Not Recruiting